Health and Human Services Secretary Robert F. Kennedy Jr. has moved to potentially broaden access to certain unapproved peptide drugs touted for wellness benefits. A draft policy filed recently allows compounding pharmacies to prepare six specified peptides, even without Food and Drug Administration (FDA) approval.
Kennedy’s policy permits the compounding of peptides like BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 under specific safeguards, offering patients a better-regulated alternative. Compounding pharmacies create specialized medications by mixing ingredients to suit individual patient needs. These peptides, while lacking FDA approval, are nonetheless marketed with health benefit claims.
“By allowing limited compounding of the substances addressed in this guidance under appropriate safeguards, the policy provides patients with a more controlled alternative,” Kennedy stated.
The Department of Health and Human Services announced it would not prosecute licensed pharmacies or physicians compounding peptide drugs, not components of FDA-approved products. Peptides act as small proteins with substantial effects. Some, like insulin, are FDA approved for safety and efficacy. Weight loss and diabetes treatments, such as GLP-1 medications, also use FDA-approved peptides.
In a recent development, an FDA advisory panel recommended allowing these unapproved peptides in compounding, though this does not equal FDA approval. FDA scientists expressed concerns about lacking enough evidence on their safety and efficacy. Kennedy cited the panel’s recommendation in his decision, emphasizing his policy as a balance between patient choice and protection.
An HHS spokesperson informed CBS News that quality testing and safety reporting are mandated for these peptide drugs. These measures help ensure patients are informed about the compounds they use from currently unregulated sources. Although the policy does not authorize FDA approval or establish clinical safety, it insists on patient-specific prescriptions, traceable ingredients, and accountability for compounders.
The policy demands FDA-registered ingredient sources, lab certification for ingredients, and reports of serious side effects. A CBS News investigation highlighted concerns when a lab test showed an experimental peptide weight-loss drug, retatrutide, lacked actual peptide content. Another investigation revealed clinics advertising retatrutide despite its non-FDA-reviewed status, as the drug remains in Eli Lilly’s clinical trials.
Kennedy’s draft policy opens for public comment from Friday to November 13. This interim policy remains until the FDA finalizes a rule on compounded peptides, which has not yet been proposed.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
Efforts to Counter Food Assistance Cutbacks in San Diego
A Personal Journey Through Encephalitis
Low-Cost Medication May Benefit Stroke Survivors
The Complex Debate Over Kratom Use in the U.S.